Publications

Journal of immunotherapy (Hagerstown, Md. : 1997)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

10-10-2018

BMC cancer

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

15-09-2018

Cranio : the journal of craniomandibular practice

The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder.

01-09-2017

Critical reviews in oncology/hematology

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

01-04-2017

Cancer treatment reviews

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

01-01-2017

Ecancermedicalscience

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology.

21-12-2016

Ecancermedicalscience

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.

03-12-2016

Ecancermedicalscience

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.

03-12-2016

BMC cancer

Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.

25-11-2016

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis.

01-06-2016

PloS one

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.

29-04-2016

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.

01-03-2016

BMC cancer

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.

06-02-2016

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Cost-effectiveness of heat and moisture exchangers compared to usual care for pulmonary rehabilitation after total laryngectomy in Poland.

01-09-2015

Breast (Edinburgh, Scotland)

Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.

01-08-2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Molecular profiling is rather likely to be cost effective.

10-05-2015

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Incidence of severe tracheobronchitis and pneumonia in laryngectomized patients: a retrospective clinical study and a European-wide survey among head and neck surgeons.

01-12-2014

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Estimating the Voi of Pivotal Studies Towards Predictive Biomarkers of High Dose Alkylating Chemotherapy in Triple Negative Breast Cancer.

01-11-2014

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Early Stage Cost-Effectiveness Analysis of a Brca1-Like Test to Detect Triple Negative Breast Cancers Responsive to High Dose Alkylating Chemotherapy.

01-11-2014

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Expert Elicitation Used for Early Technology Assessment to Inform on Cost-Effectiveness of Next Generation Sequencing.

01-11-2014

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.

01-11-2014

British journal of cancer

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

26-08-2014

Breast cancer research and treatment

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

01-06-2014

European journal of cancer (Oxford, England : 1990)

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

01-12-2013

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Value of research and value of development in early assessments of new medical technologies.

21-08-2013

International journal of cancer

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

15-08-2013

BMC research notes

Scenario drafting to anticipate future developments in technology assessment.

16-08-2012

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer.

01-02-2012

Breast cancer research and treatment

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.

01-01-2012

BMC cancer

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.

03-11-2011

Annals of surgical oncology

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

01-05-2010

European journal of cancer (Oxford, England : 1990)

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.

01-05-2010

Molecular oncology

Review on early technology assessments of nanotechnologies in oncology.

01-12-2009

International journal of technology assessment in health care

Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.

01-01-2009

Tumori

Early phase Technology Assessment of nanotechnology in oncology.

21-06-2008

The Lancet. Oncology

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

01-12-2007

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.

The cost-effectiveness of TheraBite® as treatment for acute myogenic temporomandibular disorder.

Imaging performance in guiding response to neoadjuvant therapy according to breast cancer subtypes: A systematic literature review.

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology.

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis.

Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.

Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis.

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.

A cost-effectiveness analysis of using TheraBite in a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.

Cost-effectiveness of heat and moisture exchangers compared to usual care for pulmonary rehabilitation after total laryngectomy in Poland.

Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.

Molecular profiling is rather likely to be cost effective.

Incidence of severe tracheobronchitis and pneumonia in laryngectomized patients: a retrospective clinical study and a European-wide survey among head and neck surgeons.

Estimating the Voi of Pivotal Studies Towards Predictive Biomarkers of High Dose Alkylating Chemotherapy in Triple Negative Breast Cancer.

Early Stage Cost-Effectiveness Analysis of a Brca1-Like Test to Detect Triple Negative Breast Cancers Responsive to High Dose Alkylating Chemotherapy.

Expert Elicitation Used for Early Technology Assessment to Inform on Cost-Effectiveness of Next Generation Sequencing.

Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

Prospective cost-effectiveness analysis of genomic profiling in breast cancer.

Value of research and value of development in early assessments of new medical technologies.

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

Scenario drafting to anticipate future developments in technology assessment.

Integration of a smoking cessation program in the treatment protocol for patients with head and neck and lung cancer.

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance.

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.

Review on early technology assessments of nanotechnologies in oncology.

Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.

Early phase Technology Assessment of nanotechnology in oncology.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

This site uses cookies